Glenmark’s GBR 1342 Receives the US FDA’s Orphan Drug Designation for Multiple Myeloma

 Glenmark’s GBR 1342 Receives the US FDA’s Orphan Drug Designation for Multiple Myeloma

Glenmark’s GBR 1342 Receives the US FDA’s Orphan Drug Designation for Multiple Myeloma

Shots:

  • The US FDA has granted Orphan drug designation to GBR 1342 for the treatment of multiple myeloma who have received prior therapies. The P-I study will assess the safety & tolerability of increasing doses of GBR 1342 and will evaluate biomarkers, immunogenicity, and additional measures of disease activity
  • The ODD is granted to novel drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases affecting people less than 200,000 in the US
  • GBR 1342 is a bispecific investigational Ab based on Glenmark’s BEAT technology and is designed to bind to both CD3 and CD38, activating T cells and redirecting them toward CD38+ tumor cells found in multiple myeloma

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Black Pepper Exhibition

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post